Carsten Niemann, MD, PhD, a chief physician, and head of Laboratory at the Rigshospitalet Copenhagen University Hospital, discusses notable data on patient survival outcomes, as well as the impact of minimal residual disease (MRD) in the peripheral blood from the phase 3 GLOW trial (NCT03462719) in patients with chronic lymphocytic leukemia (CLL).

The main goal of the phase 3 GLOW study was to examine progression-free survival (PFS) in patients treated with a fixed duration of ibrutinib (Imbruvica) plus venetoclax (Venclexta) vs chlorambucil and obinutuzumab (Gazyva) in the first-line setting of CLL.

When an overall survival benefit was seen in this patient population, it came as a surprise due to the fact that there are many viable next-line treatment options for patients, Niemann begins. Moreover, a majority of patients who were receiving treatment with chlorambucil and obinutuzumab received a BTK or BCL-2 inhibitor in subsequent lines of therapy, Niemann explains. These data indicate that lower survival outcomes should not be attributed to a lack of access to next-line treatment, but rather should be attributed to a lack of effective upfront therapy options, Niemann explains.

Furthermore, it is important to look at the differences seen in terms of targeting various areas of an individual patient’s CLL, such as the bone marrow, blood, and lymph nodes. Clinicians observed lymph node responses in patients with detectable vs undetectable MRD. Specifically, it was found that patients who presented with detectable MRD in the peripheral blood had sustained lymph node responses, Niemann adds.

Treatment for patients with BTK and BCL-2 inhibitor combination regimens, this may correlate with undetectable MRD levels and superior PFS.

Videos

Carsten Niemann, MD, PhD, discusses notable data on patient survival outcomes, as well as the impact of minimal residual disease in the peripheral blood from the phase 3 GLOW trial in patients with chronic lymphocytic leukemia.

Dr. Niemann on Notable Findings from the GLOW Trial in CLL

Carsten Niemann, MD, PhD, chief physician, head of Laboratory, Rigshospitalet Copenhagen University Hospital, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) vs chlorambucil and obinutuzumab (Gazyva) in mutated chronic lymphocytic leukemia (CLL).

The phase 3 GLOW study (NCT03462719) examined progression-free survival (PFS) with ibrutinib plus venetoclax vs chlorambucil and obinutuzumab in the first-line setting.

With longer follow-up, investigators found that patients with unmutated 

 who have detectable minimal residual disease (MRD) have shorter PFS, Niemann says. Notably, 

unmuted patients achieving undetectable MRD levels after treatment have a good PFS rate above 90% at 3.5 years of follow-up.

 mutations have favorable PFS regardless of MRD status, Niemann concludes.

Carsten Niemann, MD, PhD, discusses ibrutinib plus venetoclax vs chlorambucil and obinutuzumab in mutated chronic lymphocytic leukemia.

Carsten Niemann, MD, PhD

Articles

Dr. Niemann on Notable Findings from the GLOW Trial in CLL

Dr. Niemann on Ibrutinib Plus Venetoclax Vs Chlorambucil and Obinutuzumab in Mutated CLL